Clinical trial
Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid…
NCT00210041 · Institut Claudius Regaud, Other · Completed
Key facts
| NCT number | NCT00210041 |
|---|---|
| Title | Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma |
| Official title | Phase 2 Study for Treatment of Penis Epidermoid Carcinoma Loco-regionally Advanced or Metastatic by Association Gemcitabine-Cisplatin |
| Lead sponsor | Institut Claudius Regaud, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Genital Neoplasms, Male |
| Intervention type | Drug |
| Interventions | Gemcitabine, Cisplatin |
| Enrollment | 50 |
| Start date | Feb 1, 2004 |
| Primary completion | Dec 1, 2011 |
| Completion | Dec 1, 2012 |
| First posted | Sep 21, 2005 |
| Last update posted | Mar 31, 2015 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: